Enoblituzumab, previously known as TJ-271 or MGA271, represents the innovative monoclonal targeting CD33, an antigen found predominantly on blood tissues. This agent functions as the bispecific molecule, concurrently https://phoenixqmjs285279.activoblog.com/52040140/enoblituzumab-a-deep-dive-into-tj-271-and-mga271